Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Pharmaniaga Bhd's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.05.
Pharmaniaga Bhd's long-term debt to total assets ratio
stayed the same
from Mar. 2025 (0.05) to Mar. 2026 (0.05).
Pharmaniaga Bhd (XKLS:7081) LT-Debt-to-Total-Asset Explanation
LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.
Pharmaniaga Bhd LT-Debt-to-Total-Asset Related Terms
Pharmaniaga Bhd LT-Debt-to-Total-Asset Historical Data
* Premium members only.
The historical data trend for Pharmaniaga Bhd's LT-Debt-to-Total-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmaniaga Bhd (XKLS:7081) has a LT-Debt-to-Total-Asset of 0.05 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Pharmaniaga Bhd and its competitors.
Is Pharmaniaga Bhd's LT-Debt-to-Total-Asset too high?
Pharmaniaga Bhd's current LT-Debt-to-Total-Asset is 0.05. Overall, Pharmaniaga Bhd has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pharmaniaga Bhd's LT-Debt-to-Total-Asset compare to MCK and COR?
Pharmaniaga Bhd's LT-Debt-to-Total-Asset of 0.05 can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Medical Distribution company?
A good LT-Debt-to-Total-Asset depends on the Medical Distribution industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Pharmaniaga Bhd and its competitors. Pharmaniaga Bhd's current LT-Debt-to-Total-Asset is 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaniaga Bhd stock overvalued right now?
Based on GuruFocus' analysis, Pharmaniaga Bhd (XKLS:7081) is currently considered Significantly Overvalued. The stock's GF Value™ is RM0.70, compared to a current price of RM1.17 — trading 67.1% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.05. Pharmaniaga Bhd's overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Pharmaniaga Bhd (XKLS:7081), the current LT-Debt-to-Total-Asset is 0.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmaniaga Bhd (XKLS:7081) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmaniaga Bhd stock appears to be overvalued.
The current stock price of RM1.17 is trading 67.1% above its estimated GF Value™ of RM0.70.
GuruFocus considers Pharmaniaga Bhd to be Significantly Overvalued.
Key valuation signals for XKLS:7081:
LT-Debt-to-Total-Asset: 0.05
GF Value™: RM0.70 vs. price of RM1.17 (67.1% above fair value)
No single metric tells the full story. See the XKLS:7081 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmaniaga Bhd is engaged in the manufacture of pharmaceuticals and medical devices. The company is also involved in logistics and distribution. The group operates in three segments - Logistics and distribution, Manufacturing in Malaysia, and Manufacturing and distribution in Indonesia. Maximum revenue is generated by the logistics and distribution segment in Malaysia. The Logistics and distribution segment is engaged in distribution, trading and wholesaling of pharmaceutical and medical products as well as supply and installation of medical and hospital equipment in Malaysia.
45GF Score
Get the complete analysis for XKLS:7081
LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:7081 has been successfully added to your 
